For the quarter ended December 2023, Pacira (PCRX - Free Report) reported revenue of $181.24 million, up 5.4% over the same period last year. EPS came in at $0.89, compared to $0.80 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $180.6 million, representing a surprise of +0.36%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.89.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Pacira performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total net product sales: $179.76 million versus $179.41 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +4.8% change.
- Net product sales- ZILRETTA: $28.71 million versus the five-analyst average estimate of $29.15 million. The reported number represents a year-over-year change of +2.6%.
- Net product sales- Royalty revenue: $1.48 million versus $0.82 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +302.2% change.
- Net product sales- EXPAREL: $143.92 million versus $143.03 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +4.3% change.
- Net product sales- iovera: $6.04 million versus $5.94 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +32.3% change.
- Net product sales- Bupivacaine liposome injectable suspension: $1.10 million versus the five-analyst average estimate of $1.43 million. The reported number represents a year-over-year change of +9.3%.
View all Key Company Metrics for Pacira here>>>Shares of Pacira have returned -8.2% over the past month versus the Zacks S&P 500 composite's +3.9% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
For the quarter ended December 2023, Pacira (PCRX - Free Report) reported revenue of $181.24 million, up 5.4% over the same period last year. EPS came in at $0.89, compared to $0.80 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $180.6 million, representing a surprise of +0.36%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.89.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Pacira performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total net product sales: $179.76 million versus $179.41 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +4.8% change.
- Net product sales- ZILRETTA: $28.71 million versus the five-analyst average estimate of $29.15 million. The reported number represents a year-over-year change of +2.6%.
- Net product sales- Royalty revenue: $1.48 million versus $0.82 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +302.2% change.
- Net product sales- EXPAREL: $143.92 million versus $143.03 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +4.3% change.
- Net product sales- iovera: $6.04 million versus $5.94 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +32.3% change.
- Net product sales- Bupivacaine liposome injectable suspension: $1.10 million versus the five-analyst average estimate of $1.43 million. The reported number represents a year-over-year change of +9.3%.
View all Key Company Metrics for Pacira here>>>Shares of Pacira have returned -8.2% over the past month versus the Zacks S&P 500 composite's +3.9% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Get the latest research report on PCRX - FREE